Pharma approach

General anaesthetics and oxygen  Inhalational medicines  halothane   Inhalation. isoflurane   Inhalation. nitrous oxide  Inhalation. oxygen  Inhalation(medicinal gas). Injectable medicines  ketamine Injection: 50mg (as hydrochloride)/ml in 10‐ml vial. propofol Injection:  10mg/ml;20mg/ml. Thiopental may be used as an alternative depending on local availability and cost.  Local anaesthetics bupivacaine Injection: 0.25%; 0.5% (hydrochloride) in vial. Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4‐ml ampoule to be mixed with 7.5% glucose solution.   lidocaine Injection: 1%; 2% (hydrochloride)in vial Injection for spinal anaesthesia: 5% (hydrochloride) in 2‐ml ampoule to be mixed with 7.5% glucose solution. Topical forms: 2% to 4% (hydrochloride).  lidocaine + epinephrine (adrenaline)   Dental cartridge: 2% (hydrochloride) + epinephrine 1:80 000. Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial.  Compleme

1. Streptomycin:  Acute infections: 1 g (0.75 g in those above 50 yr age) i.m. (15 mg/kg) BD for 7–10 days. Tuberculosis: 1 g or 0.75 g i.m. OD or twice weekly for 30–60 days; AMBISTRYN–S 0.75, 1 g dry powder per vial for inj. 2. Gentamicin:  3–5 mg/kg/day i.m. in a single dose or divided in 8 hourly doses (dose reduction needed in elderly and in renal insufficiency), 0.1–0.3% topically in eye or on skin. GARAMYCIN, GENTASPORIN, GENTICYN 20, 60, 80, 240 mg per vial inj; also 0.3% eye/ear drops, 0.1% skin cream. 3. Kanamycin:  0.5 g i.m. BD–TDS: KANAMYCIN, KANCIN, KANAMAC 0.5, 1 g inj. 4. Tobramycin:  3–5 mg/kg day i.m. in 1–3 doses; TOBACIN 20, 60, 80 mg in 2 ml inj. 0.3% eye drops. TOBRANEG 20, 40, 80 mg per 2 ml inj., TOBRABACT 0.3% eye drops. 5. Amikacin:  15 mg/kg/day i.m. in 1–3 doses; urinary tract infection 7.5 mg/kg/day; AMICIN, MIKACIN, MIKAJECT 100 mg, 250 mg, 500 mg in 2 ml inj. 6. Sisomicin:  3–5 mg/kg/day i.m.; ENSAMYCIN, SISOPTIN 50 mg, 10 mg (pedi

  Note: Insert CTC proposed in Cell # E15 C o m p o n e n t s % a g e M o n t h l y A n n u a l B a s i c P a y 4 0 20,667 248,000   H o u s e R e n t A l l o w a n c e 1 2 6,200 74,400   S p e c i a l A l l o w a n c e 1 703 8,440   C a r L e a s e O p t i o n 2 9 15,000 180,000   L e a v e T r a v e l A l l o w a n c e ( L T A ) - - -   C o n v e y a n c e A l l o w a n c e 8 0 0 9,600   M e d i c a l A l l o w a n c e 1 , 2 5 0 15,000   M e a l V o u c h e r s 1 , 1 0 0 13,200   E S I C o n t r i b u t i o n b y E m p l o y e r - -   P F C o n t r i u b t i o n b y E m p l o y e r 7 8 0 9,360   Y e a r l y P e r f o r m a n c e B o n u s 5 , 1 6 7 62,000 620,000   G r o s s C T C 1 0 0 51,667 620,000   -   P r o f e s s i o n s T a x 1 8 3 2,190   P F C o n t r i u b t i o n b y E m p l o y e r 7 8 0 9,360   P F C o n t r i u b t i o n b y E m p l o y e e 7 8 0 9,360   E S I C o n t r i b u t i o n b y E m p l o y e r - -   E S I C o n t r i b u t i o n b y

This is to inform you that your resignation has been accepted and you are relieved from the services of laborate pharma on the close of working hours on 5 july 2018. You are requested to deposit the company Id .We wish you all success in your future endeavors. Best Wishes, ALL THE BEST.                                       TO WHOMSOVER IT MAY CONCERN     This is to certify that Mr. BHUPESH SOLANKI   was working at LABORATE PHARMACEUTICAL INDIA LTDAs PRODUCTION CHMIST   from 1 JUNE 2017 to 5 JULY 2018. During his tenure, we found him to be good knowledge and good practice his services were found to be satisfactory. We wish him all the best in his future endeavors